- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Pancreatic cancer
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1.2KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 495KB)
Irinotecan – March 2024
Irinotecan (nanoliposomal): Solution for I.V. infusion containing nanoliposomal irinotecan (as sucrosofate) 43 mg in 10 mL; Onivyde®
Last updated
30 May 2025
